Relationships between Plasma Pyrophosphate, Vascular Calcification and Clinical Severity in Patients Affected by Pseudoxanthoma Elasticum
Open Access
- 5 May 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2588
Abstract
Pseudoxanthoma elasticum (PXE; OMIM 264800) is an autosomal recessive metabolic disorder characterized by progressive calcification in the skin, the Bruch’s membrane, and the vasculature. Calcification in PXE results from a low level of circulating pyrophosphate (PPi) caused by ABCC6 deficiency. In this study, we used a cohort of 107 PXE patients to determine the pathophysiological relationship between plasma PPi, coronary calcification (CAC), lower limbs arterial calcification (LLAC), and disease severity. Overall, our data showed a deficit in plasma PPi in PXE patients compared to controls. Remarkably, affected females showed higher PPi levels than males, but a lower LLAC. There was a strong correlation between age and PPi in PXE patients (r = 0.423, p < 0.0001) but not in controls (r = 0.059, p = 0.828). A weak correlation was found between PPi and CAC (r = 0.266, p < 0.02); however, there was no statistically significant connection with LLAC (r = 0.068, p = 0.518) or a severity score (r = 0.077, p = 0.429). Surprisingly, we found no significant correlation between plasma alkaline phosphatase activity and PPi (r = 0.113, p = 0.252) or between a 10-year cardiovascular risk score and all other variables. Multivariate analysis confirmed that LLAC and CAC were strongly dependent on age, but not on PPi. Our data showed that arterial calcification is only weakly linked to circulating PPi levels and that time (i.e., age) appears to be the major determinant of disease severity and calcification in PXE. These data are important to better understand the natural history of this disease but also for the follow-up and management of patients, and the design of future clinical trials. Our results also show that PPi is not a good biomarker for the evaluation of disease severity and progression.Keywords
Funding Information
- Angers University Hospital; the French Government (National Research Agency, ANR); the National Institutes of Health (#49RC08_0018; #ANR-21-CE17-0036-02; P20GM113134)
This publication has 36 references indexed in Scilit:
- The Contribution of Arterial Calcification to Peripheral Arterial Disease in Pseudoxanthoma ElasticumPLOS ONE, 2014
- ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide releaseProceedings of the National Academy of Sciences, 2013
- Characterization of Cardiovascular Involvement in Pseudoxanthoma Elasticum FamiliesArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6 −/− )Journal of Molecular Medicine, 2013
- Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT)Diabetes Care, 2012
- Quantification of the Calcification Phenotype of Abcc6-Deficient Mice with Microcomputed TomographyThe American Journal of Pathology, 2012
- Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findingsAmerican Journal of Medical Genetics Part A, 2010
- Annual Progression of Coronary Calcification in Trials of Preventive TherapiesArchives of internal medicine (1960), 2009
- Mutation detection in the ABCC6 gene and genotype phenotype analysis in a large international case series affected by pseudoxanthoma elasticumJournal of Medical Genetics, 2007
- Quantification of coronary artery calcium using ultrafast computed tomographyJACC, 1990